NCT05348161

Dynamic Multiomics Evaluation of Anti-HER2 and Immunotherapy in HER2 Positive Gastric Cancer

• Status: Unknown
• Phase: N/A
• Study type: Interventional
• Enrollment: 100 (estimated)
• Sponsor: Peking University · Academic / Other
• Sex: All
• Age: 18 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

Dynamic multiomics explore the efficacy and mechanism of anti-HER2 \& immunotherapy of HER2 Positive GC

Detailed description

The investigators will recruit 100 HER2 positive advanced gastric cancer patients.Blood and tumor tissue will be collected at treatment baseline, every time point response till disease progression. All samples will be processed by next-generation sequence , 10× genomics single-cell sequence ,whole exon sequence, proteome detection and CTC detection to explore the efficacy and mechanism of anti-HER2 \& immunotherapy of HER2 positive GC.

Conditions

• HER2 Positive Advanced Gastric Cancer

Interventions

Type	Name	Description
PROCEDURE	Samples including blood and tissue collection	Tissue and peripheral blood sample of 100 gastric cancer patients will be collected at the baseline and time point response of therapy.
PROCEDURE	CTC detection	Peripheral blood collected from patients will be administrated to CTC detection.
PROCEDURE	ctDNA detection	DNA extraction from patients' peripheral blood will be measured by 741 panel DNA sequence.
PROCEDURE	10×genomics single cell RNA sequence	Tissue collected from patients will be digested into single cell suspension and administrated to 10×genomics single cell RNA sequence.
PROCEDURE	Whole exon sequence	DNA will be extracted from patients' tissue and administrated to whole exon sequence.
PROCEDURE	Proteomics detection	Peripheral blood collected from patients will be administrated to proximity extension assay .

Timeline

• Start date: 2019-01-01
• Primary completion: 2023-01-01
• Completion: 2025-01-01
• First posted: 2022-04-27
• Last updated: 2022-04-27

Locations

1 site across 1 country: China